Home » Stocks » FENC

Fennec Pharmaceuticals Inc. (FENC)

Stock Price: $6.61 USD -0.01 (-0.15%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
Market Cap 172.04M
Revenue (ttm) 170,000
Net Income (ttm) -19.02M
Shares Out 26.00M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $6.61
Previous Close $6.62
Change ($) -0.01
Change (%) -0.15%
Day's Open 6.64
Day's Range 6.50 - 6.70
Day's Volume 33,305
52-Week Range 4.80 - 10.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

RESEARCH TRIANGLE PARK, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circu...

4 weeks ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique ...

1 month ago - GlobeNewsWire

The FDA has accepted for review Fennec Pharmaceuticals Inc's (NASDAQ: FENC) resubmitted marketing application seeking approval for Pedmark (formulated sodium thiosulfate) to prevent ototoxicity induced ...

1 month ago - Benzinga

~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~

1 month ago - GlobeNewsWire

Fennec Pharmaceuticals Inc (NASDAQ: FENC) has resubmitted its marketing application to the FDA seeking approval for Pedmark (formulated sodium thiosulfate) for the prevention of ototoxicity (toxic to th...

2 months ago - Benzinga

~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for t...

2 months ago - GlobeNewsWire

~ Fennec Remains on Track to Finalize and Resubmit the New Drug Application for PEDMARK™ to the U.S. Food and Drug Administration in the Second Quarter of 2021 ~

2 months ago - GlobeNewsWire

~ Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for PEDMARK™ ~

3 months ago - GlobeNewsWire

~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™  ~

8 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - November 2, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ: FENC...

8 months ago - Newsfile Corp

NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. between February 11, 2020 and August 10, 202...

8 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - November 2, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of F...

8 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 2, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" o...

8 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - November 2, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmace...

8 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - October 30, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between Fe...

8 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $FENC #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 2, 2020 deadline to file a lead plaintiff motion in the class action file...

8 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC)...

8 months ago - Business Wire

Los Angeles, California--(Newsfile Corp. - October 30, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceu...

8 months ago - Newsfile Corp

LOS ANGELES, Oct. 29, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Middle District of North Caroli...

8 months ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - October 29, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceu...

8 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)-- #Fennec--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States D...

9 months ago - Business Wire

NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between February 11, 2020 an...

9 months ago - PRNewsWire

BENSALEM, Pa., Oct. 28, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming November 2, 2020 deadline to file a lead plaintiff motion in the class action filed on behal...

9 months ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - October 28, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceu...

9 months ago - Newsfile Corp

LOS ANGELES, Oct. 27, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming November 2, 2020 deadline to file a lead plaintiff motion in the class action filed on be...

9 months ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - October 27, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceu...

9 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - October 23, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between F...

9 months ago - Newsfile Corp

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class actio...

9 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - October 12, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between Fe...

9 months ago - Newsfile Corp

NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between February 11, 2020 and...

9 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - October 7, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Fe...

9 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC)...

9 months ago - Business Wire

New York, New York--(Newsfile Corp. - October 5, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between Feb...

9 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - September 28, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between...

10 months ago - Newsfile Corp

LOS ANGELES, Sept. 25, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Middle District of North Carol...

10 months ago - PRNewsWire

RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a uni...

10 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - September 20, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc.

10 months ago - Newsfile Corp

LOS ANGELES, Sept. 17, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming November 2, 2020 deadline to file a lead plaintiff motion in the class action filed on b...

10 months ago - PRNewsWire

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Middle District of North Carolina on behalf of purchasers of Fennec Pharmaceutica...

10 months ago - Business Wire

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Fennec Pharmaceuti...

10 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - September 12, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc.

10 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - September 11, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fennec Pharmaceuticals Inc.

10 months ago - Newsfile Corp

BENSALEM, Pa.--(BUSINESS WIRE)---- $FENC #classaction--Deadline Reminder:Law Offices of Howard G.

10 months ago - Business Wire

New York, New York--(Newsfile Corp. - September 11, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Fennec Pharmaceuticals Inc.

10 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that purchased or acquired ...

10 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $FENC #FENC--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc.

10 months ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $FENC #classaction--INVESTOR ALERT: Law Offices of Howard G.

10 months ago - Business Wire

New York, New York--(Newsfile Corp. - September 7, 2020) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...

10 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)---- $FENC #classaction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Car...

10 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $FENC #FENC--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc.

10 months ago - Business Wire

About FENC

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Trian... [Read more...]

Industry
Biotechnology
IPO Date
Jun 5, 2001
CEO
Rostislav Raykov
Employees
9
Stock Exchange
NASDAQ
Ticker Symbol
FENC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for FENC stock is "Strong Buy." The 12-month stock price forecast is 13.40, which is an increase of 102.72% from the latest price.

Price Target
$13.40
(102.72% upside)
Analyst Consensus: Strong Buy